Context: Carbohydrate (CHO) and caffeine (CAF) both improve endurance performance. Purpose: To determine by systematic literature review coupled with meta-analysis whether CAF ingested with CHO (CHO+CAF) improves endurance performance more than CHO alone. Methods: Databases were searched using the keywords caffeine, endurance, exercise, carbohydrate, and performance. Criteria for inclusion were studies that used human subjects performing an endurance-exercise performance task and included both a CHO and CHO+CAF condition. Effect sizes (ESs) were calculated as the standardized mean difference. Results: Twenty-one studies met the criteria for analysis. ESs for individual studies ranged from -0.08 (trivial effect favoring CHO) to 1.01 (large effect favoring CHO+CAF). The overall ES equaled 0.26 (95% CI 0.15-0.38, p < .001), indicating that CHO+CAF provides a small but significant performance benefit over CHO. ES was not significantly (p > .05) related to CAF dose, exercise duration, or performance-assessment method. To determine whether ES of CHO+CAF vs. CHO was different than CAF compared with water (placebo), a subgroup meta-analysis compared 36 CAF vs. placebo studies against the 21 CHO+CAF vs. CHO studies. The overall ES for the former group of studies (ES = 0.51, 95% CI 0.40-0.61) was nearly 2-fold greater than in CHO+CAF vs. CHO studies (p = .006). Conclusions: CHO+CAF ingestion provides a significant but small effect to improve endurance performance compared with CHO alone. However, the magnitude of the performance benefit that CAF provides is less when added to CHO than when added to placebo.
Nutritional ergogenic aids are commonly used by recreational and elite athletes as a method of improving performance during endurance competitions. Two ergogenic aids that have routinely been used by athletes and investigated over several decades are carbohydrate (CHO) and caffeine (CAF). It is well established that CHO ingestion during prolonged (≥1 hr), endurance exercise delays the onset of fatigue and improves exercise performance (Angus, Hargreaves, Dancey, & Febbraio, 2000; Below, Mora-Rodriguez, Gonzalez-Alonso, & Coyle, 1995; Coggan & Coyle, 1987; Coyle et al., 1983; MillardStafford, Sparling, Rosskopf, & DiCarlo, 1992; Sherman et al., 1989) . The improvement observed in enduranceexercise performance has generally been attributed to the provision of an exogenous fuel source, increased rates of CHO oxidation, and maintenance of blood glucose to optimally supply the energy requirements for sustained high-intensity exercise (Coggan & Coyle, 1991; Coyle, 1992) . Recent work has also suggested that CHO may improve endurance performance via central-nervoussystem (CNS) activation (Carter, Jeukendrup, & Jones, 2004; Del Coso, Estevez, & Mora-Rodriguez, 2008) .
The ergogenic effect of CAF during endurance exercise has also been examined extensively (Costill, Dalsky, & Fink, 1978; Graham & Spriet, 1991 Ivy, Costill, Fink, & Lower, 1979; Jackman, Wendling, Friars, & Graham, 1996) . However, several possible mechanisms, not all directly linked to energy metabolism, could explain improved endurance with CAF. It was originally postulated that performance improvements were the result of a metabolic effect; specifically, CAF increased fat oxidation (Costill et al., 1978; Ivy et al., 1979) , thereby reducing the reliance on muscle glycogen during exercise. Recent investigations have not validated this as the primary explanation for CAF's benefit (Cox et al., 2002; Graham, Helge, Maclean, Kiens, & Richter, 2000; Graham & Spriet, 1991; Jackman et al., 1996; Kovacs, Stegen, & Brouns, 1998) . Alternative mechanisms have been proposed for the ergogenicity of CAF, including those related to CNS or peripheral actions on skeletal muscle. For example, adenosine-receptor antagonism (Davis et al., 2003) in the CNS may explain the decreased perception of effort often observed with CAF during exercise (Cole et al., 1996; Cox et al., 2002; Doherty & Smith, 2005; Jacobson, Febbraio, Arkinstall, & Hawley, 2001) . Moreover, peripheral mechanisms such as improved skeletal-muscle force production may also underlie purported benefits (Lopes, Aubier, Jardim, Aranda, & Macklem, 1983; Meyers & Cafarelli, 2005) . Because CHO ingestion enhances performance by supporting vital CHO metabolism and CAF potentially acts via alternative pathways (e.g., facilitating neuromuscular force production), it is tempting to speculate that CHO combined with CAF (CHO+CAF) might prove additive in augmenting endurance-exercise performance compared with CHO alone.
To date, exercise-performance studies investigating CHO+CAF compared with CHO alone have produced mixed results. Some studies report significant performance improvements with CHO+CAF (Cox et al., 2002; Cureton et al., 2007; Kovacs et al., 1998) , and others demonstrated no additional benefit (Hunter, St. Clair Gibson, Collins, Lambert, & Noakes, 2002; Sasaki, Maeda, Usui, & Ishiko, 1987; van Nieuwenhoven, Brouns, & Kovacs, 2005) beyond ingestion of CHO alone. The reason for equivocal results is unclear but might be the variety of experimental factors across the studies, such as subject characteristics, caffeine dose, or the test selected to evaluate exercise performance. Whether CHO+CAF significantly improves performance above CHO alone could be determined by conducting a rigorous systematic review of the literature coupled with a meta-analysis. Therefore, our primary aim was to conduct a systematic review of the literature combined with meta-analysis to assess whether CHO+CAF provides an endurance-exercise performance benefit above CHO alone. Experimental factors (e.g., caffeine dose and other aspects of the test protocol to assess performance) that could account for the variability in standardized mean differences or effect size (ESs) among studies were also examined. Furthermore, to better understand whether the ergogenic effects of CHO and CAF are independent of each other (and thus potentially additive), we also examined whether the established magnitude of the ergogenic effect of CAF (compared with placebo control) for endurance is similar to that when CAF is combined with CHO, via systematic review and meta-analysis. If the ES of CAF is the same no matter what it is combined with, then it would seem that CAF's mechanism of action is independent of that of CHO (e.g., CHO facilitates metabolism, whereas CAF affects the neural or muscular systems). However, if the ES of CAF differs depending on whether it is added to CHO or placebo, this would suggest interaction or redundancy between the mechanisms of action for CAF and CHO (e.g., both influencing metabolism or CNS fatigue inhibition).
Methods

Identification of Studies for Inclusion
The databases of PubMed, SPORTDiscus, and ProQuest and conference proceedings from the American College of Sports Medicine annual meeting (from the past 19 years) were searched through April 2009. Our review used studies on human subjects with a crossover (withinsubject) research design. The studies were required to contain an endurance-exercise bout that included a performance task (i.e., exercise time to fatigue, time to complete a set amount of work, or work completed in a set amount of time) and both a CHO and CHO+CAF condition. Our operational definition of endurance performance was that the exercise-performance test per se be at least 10 min in duration. However, the studies (Cureton et al., 2007; Eschbach et al., 2002; Ganio et al., 2007) with test duration of 10-15 min were preceded by a prolonged bout of submaximal exercise, so that the total exercise duration of the test protocol was on average for all studies 94.0 min and ranged from 19.6 to 250.4 min. For inclusion in the analysis, all study protocols had to use either preexercise ingestion of CHO and CHO+CAF within 90 min prior, ingestion during exercise, or both (preexercise ingestion and at some points during exercise). Investigations that were published in peer-reviewed journals were included, as well as those available as scientific conference proceedings, theses, or dissertations (in the case of one study by MacLeod, 2004) to avoid publication bias. Publication bias, as documented previously (Borenstein, Hedges, Higgins, & Rothstein, 2009) , can occur because studies that report higher ESs are more likely to be published than those with low ESs; thus, this bias would be introduced into the meta-analysis if only published studies were included.
For the primary meta-analysis comparing CHO+CAF and CHO, the following keywords were used to search the data bases: caffeine and carbohydrate and (performance or endurance or exercise). In a supporting analysis to obtain the magnitude of the effect that CAF had compared with water (or placebo), the keywords caffeine and (performance or endurance or exercise) were used. Similar inclusion and exclusion criteria were used for the supporting analysis, with the exception that a placebo condition was used in place of a CHO condition. In addition, reference lists from related review articles on CAF were examined to further ensure that all relevant articles were included (Burke, 2008; Doherty & Smith, 2004 Ganio, Klau, Casa, Armstrong, & Maresh, 2009; Sökmen et al., 2008) .
Statistical Analysis
Data from each study were converted into the same format by calculating the standardized difference in means: (M CAF -M noCAF )/SD Pooled , where SD Pooled is the pooled standard deviation (Borenstein et al., 2009 ) and was calculated as follows:
where r no CAF,CAF is the intertrial correlation between the no-CAF and CAF conditions. In seven studies, we were able to calculate r no CAF,CAF from the reported data (Bell, McLellan, & Sabiston, 2002; Eschbach et al., 2002; French, McNaughton, Davies, & Tristram, 1991; Graham & Spriet, 1991; MacLeod, 2004; Pasman, van Baak, Jeukendrup, & De Haan, 1995; Spriet et al., 1992) , and in two instances r no CAF,CAF was obtained from the study authors (Cureton et al., 2007; Rehrer, Cusdin, & Deutsch, 1997) . For studies for which we were not able to obtain intertrial correlations, we used the mean of the reported and obtained correlations (r = .74, SD = .09, range .62-.86 for CHO+CAF vs. CHO; r = .86, SD = .12, range .68-.99 for CAF vs. placebo). The Hedges correction (Hedges's g) was used to account for potential bias resulting from the small sample sizes used in the reviewed studies. To do this, the standardized mean difference and standard error were multiplied by the following correction factor (Borenstein et al., 2009) 
In studies that reported more than one outcome, average ESs and their associated variances were used to calculate the meta-analyses' overall ESs. The overall ES was calculated using a random-effects model that accounts for true variation in effects occurring from study to study, as well as random error within a single study. The randomeffects model was chosen over a fixed-effect model because experimental factors such as caffeine dose and test protocols to assess endurance performance had wide variation. An ES of zero would indicate that there is no difference between the two treatments, a negative ES would indicate that the condition without CAF yielded better performance, and a positive ES would indicate that the condition with CAF yielded better performance outcomes. The reference points developed by Cohen (1988) were used for interpretation, that is, that ESs of 0.2, 0.5, and 0.8 were considered small, moderate, and large, respectively.
To assess whether various experimental factors could explain the variation in ES observed among the studies, subgroup meta-analyses or metaregressions (methodof-moments model) were conducted. These analyses included metaregressions of continuous data-CAF dose, duration of the performance task, and subjects' fitness level (VO 2max )-relative to study ES. Subgroup metaanalyses were used to examine the effects of categorical data: timing of CAF administration (e.g., before or during exercise), exercise mode (cycling vs. running), type of performance task (time to fatigue vs. fixed-endpoint task such as a time trial or work completed in fixed time), subjects' gender (men, women, or both), completion of an exercise bout before the performance event (yes or no), and published versus unpublished studies. Publication bias was also assessed by displaying the relationship between ESs of each study and standard error in a funnel plot combined with a trim-and-fill correction (Duval & Tweedie, 2000) . Our group previously used these techniques in a meta-analysis (Warren, Park, Maresca, McKibans, & Millard-Stafford, 2010) .
All calculations were made with the Comprehensive Meta Analysis, version 2.2 (Biostat, Englewood, NJ), software package. An α level of .05 was used for all analyses to indicate statistical significance.
Results
Study Characteristics for CHO+CAF Versus CHO Analysis
In all, 140 articles were identified for potential inclusion in the analysis. After reviewing the articles, 121 were eliminated as not meeting the inclusion criteria (e.g., an endurance performance task of at least 10 min and comparing both CHO and CHO+CAF conditions). Nineteen studies met the inclusion criteria (Table 1) : thirteen peer-reviewed research articles Cox et al., 2002; Cureton et al., 2007; Hogervorst et al., 2008; Hulston & Jeukendrup, 2008; Hunter et al., 2002; Jacobson et al., 2001; Kovacs et al., 1998; Sasaki et al., 1987; Slivka et al., 2008; van Nieuwenhoven et al., 2005) , five published abstracts from conference proceedings (Eschbach et al., 2002; Ganio et al., 2007; King et al., 2006; Rehrer et al., 1997; Smith et al., 2006) , and one unpublished master's thesis (MacLeod, 2004) . We included these well-designed scientific abstracts and thesis despite their tendency to influence the results toward a null finding. One research article (Cox et al., 2002) reported results from two independent studies, and another used two subgroups with different subjects (CAF users and nonusers). Thus, in all, 21 studies were used in the analysis.
The doses of both CAF and CHO were quite variable among these studies (as indicated in Table 1 ) and not reported in two studies MacLeod, 2004) . CAF dose in the CHO+CAF versus CHO metaanalysis ranged from 1.3 to 10.8 mg/kg body weight (median = 5 mg/kg). CHO dose ingested across the duration of exercise ranged from 23.1 to 113.6 g/hr of exercise (median 56.4 g/hr). Subjects in four studies did not consume the CHO and CAF at the same time points: CAF was consumed either 3 hr before beginning exercise (Eschbach et al., 2002) , 1 hr before beginning exercise (Rehrer et al., 1997) , or 1 hr before and during exercise (Cox Studies A and B; Cox et al., 2002) . The CAF was ingested in the form of a capsule Cox et al., 2002; Eschbach et al., 2002; Hunter et al., 2002; Jacobson et al., 2001; Rehrer et al., 1997; Slivka et al., 2008) , dissolved in a drink (Cureton et al., 2007; Ganio et al., 2007; Hulston & Jeukendrup, 2008; King et al., 2006; Kovacs et al., 1998; MacLeod, 2004; Sasaki et al., 1987; van Nieuwenhoven et al., 2005) , or contained in a performance bar (Hogervorst et al., 2008) . Only three studies used a CHO condition that contained only CHO (plus flavoring; MacLeod, 2004; Rehrer et al., 1997; Sasaki et al., 1987) . In most of the other studies, the CHO condition was a sports drink with electrolytes Cox et al., 2002; Cureton et al., 2007; Eschbach et al., 2002; Ganio et al., 2007; Hunter et al., 2002; King et al., 2006; Kovacs et al., 1998; Smith et al., 2006; van Nieuwenhoven et al., 2005) . Two studies included in the analysis (Cureton et al., 2007; Ganio et al., 2007) used slightly different CHO-drink concentrations (~1%) between the CHO and CHO+CAF study conditions; however, both were commercially available sports drinks, and CHO doses were within a range previously determined to be ergogenic (Coyle, 1992; Coyle et al., 1983) . The CHO+CAF in those two studies also included small amounts of other ingredients (e.g., taurine, carnitine) that are not currently known to be ergogenic at the levels consumed. The 21 studies yielded a total of 333 subjects, with 93% being men. The median number of subjects in a study was 11. Subjects were well trained, with mean VO 2max ranging among the studies from 51 to 71 ml · kg -1 · min -1 . The average percentage performance difference reported in the studies (last column in Table 1 ) suggests that CHO+CAF might result in a 6% performance improvement versus CHO. Note. CHO = carbohydrate; CAF = caffeine; VO 2max = maximal oxygen uptake; EM = exercise mode; TR = treadmill running; CE = cycle ergometer; NR = not reported; T(J) = total work in Joules; W max = maximum Watts; OR = outdoor running.
ESs for CHO+CAF Versus CHO Analysis
The ESs for the 21 studies used in our primary metaanalysis ranged from -0.08 (trivial effect favoring CHO) to 1.01 (large effect favoring CHO+CAF) and are listed in ascending order in Figure 1 . Eighteen of the 21 studies yielded a positive ES (i.e., favoring CHO+CAF). The overall ES of the meta-analysis was small in magnitude (ES = 0.26, 95% CI 0.15-0.38) but statistically different from zero (p < .001; Figure 1 ). This indicates that CHO+CAF increases endurance-exercise performance over CHO. Although the total number of available studies that met our inclusion and exclusion criteria was limited, no single study unduly influenced the results. For example, when we eliminated the study with the greatest ES, of 1.01 (a subgroup of subjects identified as CAF naïve), by , the overall ES, although reduced slightly (i.e., from 0.26 to 0.24), remained statistically significant (p < .001, 95% CI 0.13-0.34). In addition, when we eliminated the two studies that had other ingredients in the CHO+CAF trials (Cureton et al., 2007; Ganio et al., 2007) , the ES of 0.24 remained significant (p < .001, 95% CI 0.13-0.36). 
Moderator Variables for CHO+CAF Versus CHO Analysis
Additional analyses assessing the effects of moderator variables were conducted to investigate potential underlying explanations for the ES variability observed among the studies. These results are summarized in Table 2 . None of the variables probed had a significant impact on study ES variation (i.e., CAF dose, subjects' fitness level [VO 2max ], timing of CAF ingestion, mode of exercise, subject gender, or completion of a sustained endurance-exercise bout before the performance task). Because performance was the primary dependent measure of interest, and the test protocol used to assess performance has been identified as producing differential outcomes, two test protocol models were compared: a time-to-exhaustion/fatigue test (i.e., endurance capacity) in 7 studies and a fixed-endpoint task (i.e., time trial and/or performing as much work as possible in set time) in 14 studies. Because unpublished studies tend to report smaller ESs (and, often, nonsignificant findings), a subgroup metaanalysis was run on unpublished studies (n = 6) compared with published studies (n = 15). The ES for CHO+CAF versus CHO in the unpublished studies resulted in an ES of 0.13 compared with the published studies' overall ES (0.32), which tended to be different from each other (p = .09) as illustrated in Table 2 . Therefore, inclusion of the unpublished studies reduced the overall ES from 0.32 to 0.26 but did not affect the summary conclusions regarding the performance enhancement of CHO+CAF compared with CHO. Publication bias was also assessed by examining a funnel plot of the standard error versus ES. In the absence of publication bias, the studies are distributed symmetrically about the mean ES because the sampling error is random. The funnel plot illustrated a disproportionate number of studies to the right of the overall ES (favoring CHO+CAF). Using Duval and Tweedie's (2000) trim-andfill correction, six "studies" would need to be imputed into the analysis to produce symmetry about the mean ES (with studies favoring CHO). The results of the trim-and-fill correction to produce symmetry reduced the overall ES of CHO+CAF to 0.14 (95% CI 0.02-0.27), which approaches a trivial ES but is still statistically significant.
Study Characteristics for CAF Versus Placebo Analysis
In all, 152 articles were identified for potential inclusion in the analysis. Thirty-three peer-reviewed research articles met the inclusion criteria (Alves et al., 1995; Bell, Jacobs, & Zamecnik, 1998; Berglund & Hemmingsson, 1982; Bridge & Jones, 2006; Butts & Crowell, 1985; Cadarette, Levine, Berube, Posner, & Evans, 1983; Cha et al., 2001; Cohen et al., 1996; Collomp et al., 2002; Conway, Orr, & Stannard, 2003; Costill et al., 1978; Denadai & Denadai, 1998; French et al., 1991; Fulco et al., 1994; Graham, Hibbert, & Sathasivam, 1998; Graham & Spriet, 1991; Greer, Hudson, Ross, & Graham, 2001; Ivy et al., 1979; Jenkins, Trilk, Singhal, O'Conner, & Cureton, 2008; Lindinger, Graham, & Spriet, 1993; MacIntosh & Wright, 1995; McLellan, Bell, & Kamimori, 2004; McNaughton et al., 2008; Norager, Jensen, Madsen, & Laurberg, 2005; Pasman et al., 1995; Powers, Byrd, Tulley, & Callendar, 1983; Sasaki et al., 1987; Slivka et al., 2008; Spriet et al., 1992; Trice & Haymes, 1995; Van Soeren & Graham, 1998;  Table 3 ). Three research articles Berglund & Hemmingsson, 1982; Butts & Crowell, 1985) reported Note. CAF = caffeine; VO 2max = maximal oxygen uptake; EM = exercise mode; CE = cycle ergometer; NR = data not reported; XX = cross-country skiing; TR = treadmill running; SL = sea level; PS = pool swimming; W max = maximum workload; OR = outdoor running; AT = anaerobic threshold; SB = sandbag piling; expected HR max = 220 -age; TK = track running.
Table 3 (continued)
results using subgroups with different subjects. Thus, in all, 36 studies were used in the analysis. There was a total of 352 subjects in the 33 studies, with 79% of the subjects being men. Subjects' average VO 2max ranged among the studies from 37 to 75 ml · kg -1 · min -1 . The CAF dose administered ranged from 1 to 13 mg/kg (median dose 5.0 mg/kg). In addition, none of these studies reported a CHO meal within 2 hr of the test.
ESs for CAF Versus Placebo Analysis
All 36 study ESs were positive, ranging from 0.02 to 1.75. The overall ES for the meta-analysis (ES = 0.51, 95% CI 0.41-0.62) was moderate in magnitude and statistically different from zero (p < .001; Figure 2 ). As in the previous analysis, no single study unduly influenced the results. For example, when we eliminated the study with the greatest ES (1.75), the overall ES (0.49) remained statistically significant (p < .001).
Comparison of the CHO+CAF Versus CHO and CAF Versus Placebo Analyses
The subgroup meta-analysis that compared all 57 studies indicated that the ES for CHO+CAF versus CHO (ES = 0.27, 95% CI 0.14-0.41) compared with CAF versus placebo (ES = 0.51, 95% CI 0.41-0.61) was significantly different (p = .006); consequently, CAF had less of an ergogenic benefit when added to CHO than when it was added to placebo. It is important to note that this comparison was not for caffeine alone versus CAF+CHO. Only three studies would have been available to perform that analysis and, as such, were insufficient to help assess the effect of CAF alone compared with CAF+CHO.
Discussion
The unique focus of this analysis was to determine whether CAF (a well-known endurance ergogenic aid) ingested with CHO would augment the already well-documented ergogenic effect of CHO alone. Our systematic review and meta-analysis indicate that CHO+CAF ingestion can significantly improve endurance-exercise performance compared with CHO alone, with a small overall ES (0.26). This appears to also be practically relevant for endurance-sport competition because performance differences of <1% are deemed meaningful, particularly at the elite level (Hopkins, Hawley, & Burke, 1999; Hopkins, Schabort, & Hawley, 2001 ). It has previously been documented in a systematic review (Ganio et al., 2009 ) and a metaanalysis (Doherty & Smith, 2004 ) that CAF's influence on endurance-exercise performance has a moderate ES (0.63) that is similar in magnitude to that observed in the current analysis (ES = 0.51). However, we extended this finding by reporting that CAF coingested with CHO added less of a performance benefit than when CAF was added to placebo. This suggests that the benefits derived from the combination of these two ergogenic aids are not truly "additive"; otherwise the ESs should have been similar no matter what CAF was coingested with. It is therefore unlikely that the mechanisms of CAF's and CHO's actions are independent from each other when coingested, in contrast to the conclusions from at least one study used in the current analysis (Cox et al., 2002) . Those authors (Cox et al., 2002) reported that a cola beverage aided endurance-cycling performance, and when they tested CAF and CHO separately each component appeared to have independent benefits. However, if the mechanisms of action were truly independent, one would predict that the overall ES of CAF would be the same regardless of what CAF was ingested or combined with (i.e., placebo or CHO). Instead, the additional benefit of CAF when combined with CHO was small compared with moderate (vs. placebo).
If the benefit of CHO+CAF is not truly independent, what is the explanation for CHO+CAF to further improve endurance performance over CHO alone? Studies that have observed improvements in endurance-exercise performance when combining CAF with CHO have suggested potential metabolic advantages. CHO+CAF ingestion facilitated higher rates of CHO oxidation that coincided with greater exercise intensity sustained during a performance ride (Cureton et al., 2007) than with CHO alone. Furthermore, the rate of CHO oxidation observed (Yeo, Jentjens, Wallis, & Jeukendrup, 2005) was significantly higher by 26% with CHO+CAF ingestion than in the comparable exercise condition with CHO alone; this was speculated to be because of facilitated CHO absorption across the gut wall (van Nieuwenhoven, Brummer, & Brouns, 2000; Yeo et al., 2005) . However, higher CHO oxidation rates with CHO+CAF are not always reported (Sasaki et al., 1987) , and intestinal absorption data are not currently available. Moreover, glucose metabolism during exercise appears similar for CAF when not ingested with CHO (placebo conditions; Battram, Shearer, Robinson, & Graham, 2004; Graham et al., 2000; Titlow, Ishee, & Riggs, 1991; Weir, Noakes, Myburgh, & Adams, 1987) . Therefore, whether CHO+CAF provides some synergistic metabolic advantage (enhanced peak rate of CHO oxidation beyond that of ingesting CHO alone) remains to be verified as a potential mechanism underlying improved exercise performance.
Other potential mechanistic explanations by which CAF added to CHO might further improve performance are not well established. Performance improvements with CHO+CAF might be explained by CAF's additional mechanisms acting centrally or peripherally (Davis et al., 2003; Lopes et al., 1983; Meyers & Cafarelli, 2005) . As an example, CAF is a known adenosine antagonist that can block the perception of fatigue (Davis et al., 2003) , thereby explaining the lower perceived exertion observed with CAF in another meta-analysis (Doherty & Smith, 2005) . Increased force production resulting from increasing motor-unit recruitment and activity, reducing sensations of force, pain or other direct skeletal-muscle factors that result in attenuated intrinsic muscle-strength loss have previously been suggested (Cureton et al., 2007) to explain the ergogenicity of CHO+CAF. It was recently reported (Warren et al., 2010) that CAF improves maximum voluntary strength in the knee-extensor muscle group (ES = 0.37) and muscle endurance (ES = 0.28) when the test is an open-endpoint test (e.g., time to fatigue for maintenance of a submaximal isometric force). Therefore, these strength improvements in a muscle group recruited heavily during cycling could also translate into endurance performance benefits, particularly because cycling was the exercise mode used in nearly all the studies in the CHO+CAF versus CHO meta-analysis.
Another possibility is that CAF could simply be a more robust ergogenic aid than CHO alone. Whether CAF alone is equal to or superior to CHO+CAF was not addressed in our analysis; this would have been impractical because of the few studies available (n = 3) that had CAF versus CHO+CAF comparisons. Because CAF acts potentially via multiple mechanisms, some of which might mimic those of CHO (e.g., metabolic) in addition to alternative effects (e.g., CNS, neuromuscular), this cannot be ruled out. However, this is unlikely because CHO benefits are not limited to metabolic benefits (Hargreaves, 2008) .
Although the current analysis cannot provide mechanistic explanations as to why the combination of CHO+CAF is more efficacious than CHO alone, it does provide insight into factors that have been thought to influence variable results among investigations. Whether CAF dose is related to the ES of studies comparing CHO+CAF with CHO had not been previously analyzed systematically. In the few dose-response studies in our meta-analysis comparing CHO+CAF and CHO, one (Kovacs et al., 1998) found that CHO+CAF improved cycling performance at 2.1, 3.2, or 4.5 mg/kg versus CHO alone but that endurance was further enhanced at CAF doses >3 mg/kg. In contrast, another (Cox et al., 2002) reported that 1.5 and 3 mg/kg of CAF produced equally positive effects on endurance-cycling performance. Our results using metaregression indicate that CAF dose was not related to the ES of performance benefits for CHO+CAF versus CHO; however, it must be acknowledged that the dose used in the 20 studies clustered between 4 and 6 mg/kg.
To further understand the variability among studies regarding efficacy of ergogenic aids, the test protocol used to assess performance has often been cited as a potential intervening factor. Performance-test protocol has been debated over the years regarding reliability (Doyle & Martinez, 1998; Jeukendrup, Saris, Brouns, & Kester, 1996) and sensitivity (Hopkins et al., 2001) . A time-toexhaustion or open-endpoint protocol is limited in external validity because it fails to represent a task used in the competitive sport setting and produces greater variability (coefficient of variation of 27%; Jeukendrup et al., 1996) . However, when time-to-exhaustion changes are converted to equivalent changes in power output, this test produces a very reliable measure of performance (Hopkins et al., 2001) . On the other hand, although a fixed-task (timetrial) test intuitively has greater ecological validity, it can be negatively influenced by subjects' errors in pacing strategy. Recently, fixed-versus open-endpoint tests were observed to have similar sensitivity in detecting changes in endurance performance (Amann, Hopkins, & Marcora, 2008) . Moreover, the studies in the CHO+CAF versus CHO comparison (Table 1) (Table  2) , although time-to-fatigue tests tended to elicit greater ESs. A previous meta-analysis examining the effects of CAF on exercise testing also found a twofold difference between open and fixed protocols (Doherty & Smith, 2004) . The main point from the current study, however, is that both test protocols are capable of detecting the benefits of CHO+CAF as an ergogenic aid versus CHO, and, thus, the performance test used does not fully explain the variability observed in the literature.
Because there was substantial heterogeneity in study ESs for the combined effect of CHO+CAF and none of the aforementioned factors appeared to adequately explain this ES dispersion, we also examined the impact of including unpublished studies in the meta-analysis. As we would have predicted, the overall ES of unpublished studies tended to be lower than in the published studies. This suggests that if additional studies were identified or performed that resulted in an ES favoring CHO, the overall ES could eventually shift toward a trivial benefit for CHO+CAF versus CHO. A funnel plot of standard error versus ES revealed asymmetry, and when the trimand-fill correction was calculated (to artificially "adjust" the funnel plot to make the data symmetrical), including another six studies on the side favoring CHO would shift the overall ES of adding CAF to CHO to 0.14 (intermediate between a trivial and small benefit). This suggests potential publication bias and, thus, indicates a potential limitation of our systematic review (i.e., other unpublished, unidentified studies may exist) and an overall limitation in meta-analysis as a whole. Moreover, both authors and journal reviewers may not fully understand the importance of publishing studies with "null" effects to enhance accurate interpretation of the literature. So it should be recognized that as additional studies are performed (and published) over time, the current conclusions derived from this meta-analysis may be altered.
In conclusion, a systematic review and meta-analysis of the literature through early 2009 indicate that CHO+CAF ingestion before and/or during endurance exercise results in significantly improved performance compared with CHO alone. Based on the literature available, this ergogenic benefit does not appear to be directly related to factors often believed to influence results, such as the CAF dose or test protocol for endurance performance (time trial vs. time to fatigue). However, the magnitude of the performance benefit of adding CAF to CHO is less than when CAF is added to water (placebo). Future experimental investigations examining the impact of two potentially ergogenic substances ingested alone or in combination could address this issue mechanistically to advance our understanding of the limits of fatigue on endurance performance.
